Survival of Second Cancer Is Worse in Young Patients

Article

When it comes to survival rates for second cancers, younger patients had poorer outcomes than their older counterparts, according to a recent study.

Second primary cancers in pediatric and adolescents and young adult (AYA) patients are deadlier than they are in older patients, according to a new study published in JAMA Oncology.

Researchers from University of California, Davis (UC Davis), Oregon Health and Science University in Portland and the John Wayne Cancer Institute in Santa Monica, California, examined five-year survival rates and found that after a second cancer it was 33.1 percent lower for children, 20.2 percent lower for AYA patients and 8.3 percent lower for older adults compared with a primary cancer at the same age.

They determined their findings by using data from more than a million (15,954 pediatric, 125,750 AYA and 878,370 older adult) patients with cancer of all ages throughout the United States using the Surveillance, Epidemiology and End Results (SEER) program — 13 registries.

One group of patients in the study had only a one cancer, while the other group had a first cancer and then developed a second cancer.

Fourteen of the most common cancer types that affect children and AYAs were examined: female breast, thyroid, testicular, Hodgkin lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, soft tissue sarcoma, bone sarcoma, colorectal, central nervous system, cervical and ovarian cancer.

“We know from prior studies that the risk of developing a second cancer varies by age, with those diagnosed with their first cancer at a young age having a higher risk of a second cancer than those diagnosed with their first cancer later in life,” Theresa Keegan, Ph.D., M.S., associate professor in the division of hematology and oncology, UC Davis Comprehensive Cancer Center, said in an interview with CURE. “In this study, we found that the adverse impact of a second cancer on survival was most pronounced in children and AYAs compared with older adults.”

The researchers saw significant differences in survival among the common cancer types. For instance, AYA patients diagnosed with acute myeloid leukemia as a first cancer had a 57 percent chance of surviving for five years, but that dropped to 29 percent if it was the second cancer. For AYA patients diagnosed with breast cancer, the five-year survival was 81 percent for a first cancer, but 63 percent if it was a second cancer.

There are no clear explanations on why survival is worse for children and AYA patients compared with older patients. However, Keegan did offer potential reasons why survival may be worse after a second cancer at any age.

“Worse survival after second cancers may result from the second cancer being more biologically aggressive, those with a second cancer having a worse response to treatment, limitations on types or doses of treatment they can receive as a result of their prior cancer treatment or impaired physiological reserves that impair their ability to impact treatment for their second cancer,” said Keegan.

To get a broader understanding of what this all means, Keegan and the team plan to examine how the time between getting a first and second cancer affects survival and whether the type of treatment for the first cancer influences the outcome of a second cancer.

Keegan added that all cancer survivors have an increased risk of second cancers and, although the reason for this is not clear, there are cancer prevention strategies that patients and survivors can apply.

“In addition to cancer prevention behaviors, it is important for cancer survivors to undergo surveillance and screening for second cancers,” said Keegan. “Making this part of routine survivorship care allows for second cancers to be diagnosed as early as possible.”

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content